Current stock page

Catalysts

AXSM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

AXSMAxsome Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 3/10
$141.69−$2.68 (−1.86%)

Latest quote

  • Momentum
    24
  • Value
    65
  • Quality
    57
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 22, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 47/100

Momentum 24/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 27.07%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 24/100AIQ Edge 3/10 Relative Laggard
Beat rate
38%
3 of 8 reported periods
Average surprise
-7.2%
Across covered historical reports
Latest result
+60.6%
Nov 2, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 2, 2026—-$0.63-$0.25+60.6%$249.19M$259.69M
Aug 10, 2026—-$0.89-$0.99-11.0%$221.11M$216.36M
May 4, 2026—-$0.85-$1.26-48.2%$190.91M$189.4M
Feb 23, 2026—-$0.70-$0.71-1.4%$193.36M$194.7M
Nov 3, 2025—-$0.82-$0.94-14.6%$191.33M$170.99M
Aug 4, 2025—-$1.00-$0.92+8.0%$140.02M$150.04M
May 5, 2025—-$1.26-$1.22+3.2%$119.16M$121.46M
Feb 18, 2025—-$1.00-$1.54-54.0%$118.07M$118.77M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
21
Buy
1
Hold
12-month analyst target
$260.14
+83.60% versus current price
Based on 22 analyst observations. Targets are estimates, not predictions.
Low target
$238.00
+67.97% vs latest price
Average target
$260.14
+83.60% vs latest price
High target
$295.00
+108.20% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 22, 2027

Next known earnings or reporting date.

EPS estimate-$0.05

Current analyst expectation for the upcoming report.

Revenue estimate$284.03M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score24

Where event reaction would show up first.

AIQ score47/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
22
Average target
$260.14
Target upside
83.60%
Target range
$238.00 - $295.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Nov 9, 2026

Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Axsome Therapeutics, Inc. (AXSM) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 11:30 AM ESTCompany ParticipantsMark Jacobson -...

seekingalpha.com · Nov 2, 2026

Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade) (NASDAQ:AXSM)

Axsome Therapeutics is upgraded to Hold as valuation resets after ADA approval. Read the latest analysis on the stock here.

seekingalpha.com · Nov 2, 2026

Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call November 2, 2026 8:00 AM ESTCompany ParticipantsAshley DongHerriot Tabuteau - Founder, Chairman, CEO...

gurufocus.com · Oct 26, 2026

AXSM Maintained by Piper Sandler -- Price Target Lowered to $238

On October 26, 2026, analyst Piper Sandler maintained an "Overweight" rating on Axsome Therapeutics (AXSM), while lowering its price target from $258 to $238, r

finance.yahoo.com · Sep 19, 2026

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in the

Open full news and sentiment

AXSM Catalysts FAQ

What are the next catalysts for AXSM stock?

AXSM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move AXSM stock?

Upcoming events that could move AXSM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could AXSM's next earnings report affect the stock?

AXSM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive AXSM stock higher?

AXSM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt AXSM stock?

AXSM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.